文献速递心血管胸部外周血管MR

心脏磁共振成像作为未治疗肺动脉高压的预后生物标志物

Cardiac magnetic resonance imaging as a prognostic biomarker in treatment-naïve pulmonary hypertension.
PubMed 文献 · Eur J Radiol · 2019-12-10

回顾性单中心分析2013年1月1日至2019年1月1日新诊断未治疗肺动脉高压成人38例,其中12例(32%)发生临床恶化。Cox模型显示CMR测得的右心室射血分数降低(HR 0.93,p=0.007)和右心室扩张(HR 1.02,p=0.005-0.021)以及右心导管测得的肺血管阻力升高(HR 1.32,p<0.001)均独立且显著预测临床恶化,校正疾病严重程度后仍成立,且CMR与右心导管预测效能相当。

要点

  • 未治疗肺动脉高压患者中,CMR所示右心室射血分数降低(HR 0.93)和右心室扩张(HR 1.02)独立预测临床恶化。
  • CMR与右心导管对右心室功能不全的预测效能相当,不受肺动脉高压病因影响。
  • 右心导管测得的肺血管阻力升高(HR 1.32)同样独立预测临床恶化。

核心结论

  • 在未治疗肺动脉高压患者(包括WHO第II/III组)中,CMR和右心导管测得的右心室功能不全指标均独立且显著预测临床恶化,校正疾病严重程度后仍成立。

研究设计与样本

  • 回顾性单中心分析,纳入2013年1月1日至2019年1月1日新诊断未治疗肺动脉高压成人38例,其中WHO第I组动脉性肺动脉高压或WHO第II/III组肺动脉高压患者均接受CMR(Signa Horizon 1.5 T,General Electric,Milwaukee,WI和Siemens Espree 1.5 T,Munich,Germany)和右心导管检查,且在靶向治疗前完成,构建Cox比例风险模型。

关键影像表现/征象

  • CMR显示临床恶化组更常见右心室功能不全,包括右心室射血分数降低(HR 0.93,p=0.007)和右心室扩张更明显(HR 1.02,p=0.005-0.021)。
  • 右心导管显示临床恶化组肺血管阻力更差(HR 1.32,p<0.001)。

诊断标准与关键数值

  • CMR右心室射血分数降低预测临床恶化:HR 0.93,p=0.007。
  • CMR右心室扩张预测临床恶化:HR 1.02,p=0.005-0.021。
  • 右心导管肺血管阻力升高预测临床恶化:HR 1.32,p<0.001。

临床应用与阅片要点

  • 在未治疗肺动脉高压患者中,CMR测得的右心室射血分数和右心室扩张可独立预测临床恶化,与右心导管指标预测效能相当。
  • CMR和右心导管对右心室功能不全的预测效能不受肺动脉高压病因影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Targeted treatment for pulmonary arterial hypertension (PAH), diagnosed via right heart catheterization (RHC), has been shown to improve morbidity and mortality. Identifying characteristics that predict clinical worsening has been challenging. We sought to evaluate the role of cardiac Magnetic Resonance Imaging (CMR) as a predictor of clinical worsening in a cohort of treatment-naïve pulmonary hypertension (PH) patients.

METHODS: We performed a retrospective single center analysis of all adults with newly diagnosed treatment-naïve PH between January 1st 2013 and January 1st 2019. Patients with World Health Organization (WHO)-Group I PAH or WHO-Group II/III PH disease, who underwent both CMR (Signa Horizon 1.5 T, General Electric, Milwaukee, WI and Siemens Espree 1.5 T, Munich, Germany) and RHC testing prior to targeted PAH treatment, were included for analysis. Cox proportional hazards models were constructed.

RESULTS: A total of 38 patients, of which 12 (32 %) experienced the primary outcome of clinical worsening. were included in the final analysis, Patients with clinical worsening were significantly more likely to have RV dysfunction by CMR (including lower RV ejection fraction (HR 0.93, p = 0.007) and more RV dilation (HR 1.02, p = 0.005-0.021)) and RHC (including worse pulmonary vascular resistance (HR 1.32, p < 0.001)), even after adjustment for disease severity. Both CMR and RHC measures of RV dysfunction were found to be equally effective in predicting clinical worsening, regardless of PH etiology.

CONCLUSIONS: In treatment-naïve PH patients, including those with WHO-Group II/III disease, both CMR and RHC measures independently and significantly predicted clinical worsening, even after adjustment for disease severity.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Jose A, Kher A, O'Donnell RE, et al. Cardiac magnetic resonance imaging as a prognostic biomarker in treatment-naïve pulmonary hypertension. Eur J Radiol. 2019. PMID: 31862635. doi:10.1016/j.ejrad.2019.108784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。